EP Patent

EP2367537A1 — Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same

Assigned to Talphera Inc · Expires 2011-09-28 · 15y expired

What this patent protects

Compositions and methods effective to minimize or eliminate the presence of oxidative degradation products in solid dosage forms comprising sufentanil are provided.

USPTO Abstract

Compositions and methods effective to minimize or eliminate the presence of oxidative degradation products in solid dosage forms comprising sufentanil are provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP2367537A1
Jurisdiction
EP
Classification
—
Expires
2011-09-28
Drug substance claim
No
Drug product claim
No
Assignee
Talphera Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.